^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Colorectal Cancer
    Regimen:FOLFOX (5-fluorouracil + leucovorin calcium + oxaliplatin)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX

    Published date:
    07/16/2021
    Excerpt:
    In conclusion, the findings of the present study indicate that among three types of KRAS mutations, G12D/V mutations were consistently associated with less TIL infiltration and shorter RFS in two independent cohorts of stage III CRC patients treated with adjuvant FOLFOX.
    DOI:
    https://doi.org/10.1038/s41598-021-94044-4